EUVIMEDEUVIMED entdecken
Vergleichsstudie

Real-world Comparison of Avelumab Maintenance and Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma

Tsung-Han Yen, Shian-Shiang Wang, Chaun-Shu Chen, Cheng-Che Chen, Chia-Yen Lin, Sheng-Chun Hung, Gu-Shun Lai, Jian-Ri Li, Cheng-Kuang Yang, Yi-Ching Lin

Anticancer Research · 2026-07 · 46 (7) · 4107-4118

DOI: 10.21873/anticanres.18270 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Anticancer Research, online erschienen am 29.06.2026. Verfasst von Tsung-Han Yen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Urologic Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsUrologic NeoplasmsHumansFemaleRetrospective StudiesMaleAgedMiddle AgedNeoplasm Metastasis

Stichwörter der Autor:innen

AvelumabEnfortumab vedotinPembrolizumabchronic kidney diseasemetastatic urothelial carcinoma

Substanzen

avelumabAntibodies, Monoclonal, HumanizedpembrolizumabAntibodies, Monoclonalenfortumab vedotin

Autor:innen und Institutionen

  • Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan, R.O.C.
  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.
  • Department of Medicine and Nursing, Hung Kuang University, Taichung, Taiwan, R.O.C.
  • Department of Urology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.; yangck@icloud.com.
  • Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.; dianayjlin@gmail.com.

Zitieren

APA

Yen, T. H., Wang, S. S., Chen, C. S., Chen, C. C., Lin, C. Y., Hung, S. C., Lai, G. S., Li, J. R., Yang, C. K., & Lin, Y. C. (2026). Real-world Comparison of Avelumab Maintenance and Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma. Anticancer Research, 46(7), 4107-4118. https://doi.org/10.21873/anticanres.18270

Vancouver

Yen TH, Wang SS, Chen CS, Chen CC, Lin CY, Hung SC, et al. Real-world Comparison of Avelumab Maintenance and Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma. Anticancer Research. 2026;46(7):4107-4118. doi:10.21873/anticanres.18270

BibTeX
@article{Yen2026,
  author = {Yen, Tsung-Han and Wang, Shian-Shiang and Chen, Chaun-Shu and Chen, Cheng-Che and Lin, Chia-Yen and Hung, Sheng-Chun and Lai, Gu-Shun and Li, Jian-Ri and Yang, Cheng-Kuang and Lin, Yi-Ching},
  title = {Real-world Comparison of Avelumab Maintenance and Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma},
  journal = {Anticancer Research},
  year = {2026},
  volume = {46},
  number = {7},
  pages = {4107--4118},
  doi = {10.21873/anticanres.18270}
}
Kostenlos starten →